Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlitIpNi: Intratumoral myDC, Ipilimumab, and Nivolumab for Recurrent Glioblastoma
NCT03233152Phase 2Active, not recruiting
- Sponsor
- UZ Brussel
- Start
- Nov 2016
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 2 trial of autologous myeloid dendritic cells in glioblastoma (GBM), sponsored by UZ Brussel. Started Nov 2016; status: active, not recruiting.
02
Drugs
autologous myeloid dendritic cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03233152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233152.